Exelixis(EXEL) - 2023 Q3 - Earnings Call Presentation

GAAP Financial Highlights: Q3'23 (in millions, except per share amounts) 2023 Share Repurchase Program Activity (in millions, except per share amounts) 13 Commercial Update TKI = tyrosine kinase inhibitor RCC = renal cell carcinoma HCC = hepatocellular carcinoma • Strong demand and new patient starts continue to drive growth Sources: Internal Exelixis data IQVIA National Prescription Audit and BrandImpact data through 9/30/23 Safe Harbor Statement • Q3'23 collaboration services revenues primarily consist of ...